| Status | In progress |
| Process | STA 2018 |
| ID number | 1304 |
Provisional Schedule
| Committee meeting: 1 | 12 March 2020 |
| Expected publication | 27 May 2020 |
Project Team
| Project lead | Jo Ekeledo |
Email enquiries
- If you have any queries please email TACommE@nice.org.uk
| Evidence Review Group / Assessment Group | Warwick Evidence, Warwick Medical School, University of Warwick |
Consultees
| Companies sponsors | Novartis (siponimod) |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Multiple Sclerosis Society |
| Multiple Sclerosis Trust | |
| Professional groups | Association of British Neurologists |
| Royal College of Physicians | |
| UK Clinical Pharmacy Association | |
| UK Multiple Sclerosis Specialist Nurse Association |
Commentators
| Comparator companies | Novartis (interferon beta 1b) |
| Bayer (interferon beta 1b) - (confidentiality agreement not signed, not participating) | |
| Biogen (dimethyl fumarate, interferon beta 1a) | |
| Merck (interferon beta 1a) (confidentiality agreement not signed, not participating) | |
| Mylan (glatiramer acetate) (confidentiality agreement not signed, not participating) | |
| Roche (ocrelizumab) | |
| Sanofi Genzyme (teriflunomide) | |
| Teva (glatiramer acetate(confidentiality agreement not signed, not participating) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 July 2019 | Invitation to participate |
| 16 July 2019 | In progress, Appraisal has been referred to NICE. |
| 20 November 2018 - 18 December 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance